Package Leaflet: Information for the User
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe
Epoetin theta (epoetin theta)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
What is Eporatio
Eporatio contains the active substance epoetin theta (epoetin theta), which is almost identical to erythropoietin, a natural hormone produced by the body. Epoetin theta (epoetin theta) is a protein produced by biotechnology. It works exactly like erythropoietin. Erythropoietin is produced in the kidneys and stimulates the bone marrow to produce red blood cells. Red blood cells are very important for distributing oxygen within the body.
What is Eporatio used for
Eporatio is used for the symptomatic treatment of anemia and its symptoms (e.g., fatigue, weakness, and shortness of breath). Anemia occurs when blood cells do not contain enough red blood cells. Treatment for anemia is given to adult patients with chronic kidney disease or adult patients with non-myeloid cancer (cancer that does not originate in the bone marrow), who are also receiving chemotherapy (cancer medications) at the same time.
Do not use Eporatio
Warnings and precautions
General
This medicine may not be suitable for the following patients. Please consult your doctor if you belong to any of these patient groups:
Before and during treatment with this medicine, your blood pressure should be closely monitored. If your blood pressure increases, your doctor may give you medications to lower your blood pressure. If you are already being treated with medications to lower your blood pressure, your doctor may increase the dose. It may also be necessary to decrease the dose of Eporatio or interrupt treatment with Eporatio for a short period.
Consult a doctor immediately if you experience sudden, severe headache, confusion, altered speech, impaired gait, seizures, or convulsions. These may be signs of very high blood pressure, even if your blood pressure is normally normal or low. It is necessary to treat them at the same time.
Your doctor will regularly perform blood tests to monitor various blood components and their levels. Additionally, iron levels in the blood must be monitored before and during treatment with this medicine. If your iron levels are too low, your doctor may also prescribe an iron medication.
If you feel tired and weak or experience fatigue, you should consult your doctor. These symptoms could indicate that treatment with this medicine is ineffective. Your doctor will check that there are no other causes of anemia and may perform blood tests or a bone marrow examination.
The healthcare professional treating you will record exactly which product you are using at all times. This can help provide more information about the safety of medicines like this.
Healthy individuals should not use Eporatio. Using this medicine by healthy individuals can excessively increase certain blood parameters and cause heart or blood vessel problems, potentially endangering life.
Severe skin reactions, such as Stevens-Johnson syndrome (SSJ) and toxic epidermal necrolysis (TEN), have been observed with the administration of epoetins. SSJ/TEN can initially appear as red, circular spots or patches, often with central blisters on the trunk. Ulcers in the mouth, throat, nose, genitals, and eyes (eye irritation and swelling) may also appear. These severe skin reactions are often preceded by fever or flu-like symptoms. The skin rash can progress to widespread skin peeling and potentially fatal complications. If you present with a severe skin rash or any of these other skin symptoms, stop using Eporatio and contact your doctor or seek immediate medical attention.
Anemia caused by chronic kidney disease
If you are a patient with chronic kidney disease, your doctor will monitor that a certain blood parameter (hemoglobin) does not exceed the defined threshold. If blood parameters become too high, heart or vascular problems may occur, increasing the risk of death.
If you are a patient with chronic kidney disease and, in particular, if you do not respond adequately to Eporatio, your doctor will monitor your Eporatio dose, as repeated dose increases of Eporatio if you are not responding to treatment may increase the risk of heart or blood vessel problems and may increase the risk of myocardial infarction, stroke, and death.
If you have kidney blood vessel hardening (nephrosclerosis) but do not require dialysis treatment, your doctor will consider whether treatment is suitable for you. In this case, it cannot be excluded with absolute certainty that there may be an acceleration of the progression of kidney function deterioration.
If you are on dialysis, medications that prevent blood clotting are used. If you are being treated with Eporatio, the dose of the anticoagulant medication may need to be increased. Otherwise, the increase in red blood cells can cause blockage of the arteriovenous fistula (an artificial connection between an artery and a vein that is surgically created in dialysis patients).
Anemia in cancer patients
If you are a cancer patient, you should know that this medicine can act as a growth factor for blood cells and in some circumstances may have a negative impact on the cancer. Depending on the individual situation, a blood transfusion may be preferable. Please discuss this with your doctor.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age, as there are no data to demonstrate the safety and efficacy of this medicine in this age group.
Other medicines and Eporatio
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Pregnancy and breastfeeding
The use of Eporatio in pregnant women has not been investigated. It is important that you inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant, as your doctor will decide whether it is advisable for you not to use this medicine.
It is not known whether the active substance of this medicine passes into breast milk. Your doctor will decide whether it is advisable for you not to use this medicine while breastfeeding.
Driving and using machines
This medicine does not affect your ability to drive or use machines.
Eporatio contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per pre-filled syringe; this is essentially "sodium-free".
Your treatment with this medicine will be started by a doctor with experience in the previously mentioned indications.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is…
The dose of Eporatio (expressed in International Units or IU) will depend on your disease, body weight, and the route of injection administration (under the skin [subcutaneous injection] or into a vein [intravenous injection]). Your doctor will indicate the correct dose for you.
Anemia caused by chronic kidney disease
Injections can be administered under the skin or into a vein. Patients on hemodialysis normally receive the injection at the end of dialysis via the arteriovenous fistula. Patients not on dialysis treatment normally receive the injection under the skin. Your doctor will regularly perform blood tests and adjust the dose or suspend treatment if necessary. Hemoglobin values in the blood should not exceed 12 g/dl (7.45 mmol/l). Your doctor will use the lowest effective dose to control anemia symptoms. If you do not respond adequately to Eporatio, your doctor will monitor your dose and inform you if it is necessary to change the doses of Eporatio.
Treatment with Eporatio is divided into two parts:
The initial dose for subcutaneous injections is 20 IU per kg of body weight, administered 3 times a week. If necessary, your doctor will increase the dose at monthly intervals.
The initial dose for intravenous injections is 40 IU per kg of body weight, administered 3 times a week. If necessary, your doctor will increase the dose at monthly intervals.
Once an adequate number of red blood cells has been achieved, the maintenance dose required to maintain a constant number will be determined by your doctor.
In the case of subcutaneous injections, the weekly dose may be administered either as 1 injection per week or as 3 divided injections per week.
In the case of intravenous injections, the dose may be adjusted to 2 injections per week.
If you modify the frequency of dose administration, a dose adjustment may be necessary.
Treatment with Eporatio is normally long-term treatment.
The maximum dose should not exceed 700 IU per kg of body weight per week.
Anemia in cancer patients
Injections are administered under the skin. The injection will be administered once a week. The initial dose is 20,000 IU. Your doctor will regularly perform blood tests and adjust the dose or suspend treatment if necessary. Hemoglobin values in the blood should not exceed 12 g/dl (7.45 mmol/l). You will normally receive Eporatio until 1 month after completing chemotherapy.
The maximum dose should not exceed 60,000 IU.
How are the injections administered?
This medicine is administered by injection using a pre-filled syringe. The injection is administered either into a vein (intravenous injection) or into the tissue just under the skin (subcutaneous injection).
If you receive Eporatio treatment as a subcutaneous injection, your doctor may suggest that you learn to inject this medicine yourself. Your doctor or nurse will give you instructions on how to do this. Do not attempt to administer this medicine yourself without these instructions. Part of the information you need to use the pre-filled syringe can be found at the end of this leaflet (see section 7, "Information for self-injection"). However, for optimal treatment of your disease, close and constant cooperation with your doctor is required.
Each pre-filled syringe is for single use only.
If you use more Eporatio than you should
Do not increase the dose that your doctor has prescribed. If you think you have injected more Eporatio than you should, consult your doctor. It is unlikely to be serious. Even with very high levels in the blood, no symptoms of poisoning have been observed.
If you forget to use Eporatio
If you have forgotten an injection or have injected too little, tell your doctor. Do not use a double dose to make up for forgotten doses.
If you stop treatment with Eporatio
Before stopping treatment with this medicine, consult your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects:
Consult a doctor immediately if you experience sudden, severe headache, confusion, altered speech, impaired gait, seizures, or convulsions. These may be signs of very high blood pressure (frequent in patients with chronic kidney disease, may affect up to 1 in 10 people), even if your blood pressure is normally normal or low. It is necessary to treat them at the same time.
Allergic reactions such as skin rash, itching over large areas of skin, severe allergic reactions with weakness, low blood pressure, difficulty breathing, and swelling of the face (frequency not known, cannot be estimated from the available data) have been reported. If you think you have had this type of reaction, you must stop treatment with Eporatio and seek immediate medical attention.
You may experience the following additional side effects:
Frequent (may affect up to 1 in 10 people)
Frequent in patients with chronic kidney disease (may affect up to 1 in 10 people)
Frequent in cancer patients (may affect up to 1 in 10 people)
Frequency not known in patients with chronic kidney disease (cannot be estimated from the available data)
Frequency not known in cancer patients (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2°C - 8°C).
Do not freeze.
Keep the pre-filled syringe in the outer carton to protect it from light.
You may take Eporatio out of the refrigerator and store it at a temperature not above 25°C for a period of up to 7 days without exceeding the expiry date. Once it is taken out of the refrigerator, the medicine must be used within this time period or discarded.
Do not use this medicine if you notice turbidity or particles in the solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Eporatio
Eporatio 1,000 UI/0.5 ml: A pre-filled syringe contains 1,000 international units (UI) (8.3 micrograms) of epoetin zeta (epoetin theta) in 0.5 ml of injectable solution equivalent to 2,000 international units (UI) (16.7 micrograms) per ml.
Eporatio 2,000 UI/0.5 ml: A pre-filled syringe contains 2,000 international units (UI) (16.7 micrograms) of epoetin zeta (epoetin theta) in 0.5 ml of injectable solution equivalent to 4,000 international units (UI) (33.3 micrograms) per ml.
Eporatio 3,000 UI/0.5 ml: A pre-filled syringe contains 3,000 international units (UI) (25 micrograms) of epoetin zeta (epoetin theta) in 0.5 ml of injectable solution equivalent to 6,000 international units (UI) (50 micrograms) per ml.
Eporatio 4,000 UI/0.5 ml: A pre-filled syringe contains 4,000 international units (UI) (33.3 micrograms) of epoetin zeta (epoetin theta) in 0.5 ml of injectable solution equivalent to 8,000 international units (UI) (66.7 micrograms) per ml.
Eporatio 5,000 UI/0.5 ml: A pre-filled syringe contains 5,000 international units (UI) (41.7 micrograms) of epoetin zeta (epoetin theta) in 0.5 ml of injectable solution equivalent to 10,000 international units (UI) (83.3 micrograms) per ml.
Eporatio 10,000 UI/1 ml: A pre-filled syringe contains 10,000 international units (UI) (83.3 micrograms) of epoetin zeta (epoetin theta) in 1 ml of injectable solution equivalent to 10,000 international units (UI) (83.3 micrograms) per ml.
Eporatio 20,000 UI/1 ml: A pre-filled syringe contains 20,000 international units (UI) (166.7 micrograms) of epoetin zeta (epoetin theta) in 1 ml of injectable solution equivalent to 20,000 international units (UI) (166.7 micrograms) per ml.
Eporatio 30,000 UI/1 ml: A pre-filled syringe contains 30,000 international units (UI) (250 micrograms) of epoetin zeta (epoetin theta) in 1 ml of injectable solution equivalent to 30,000 international units (UI) (250 micrograms) per ml.
Product Appearance and Container Contents
Eporatio is a clear and colorless injectable solution in a pre-filled syringe with a needle for injection.
Eporatio 1,000 UI/0.5 ml, Eporatio 2,000 UI/0.5 ml, Eporatio 3,000 UI/0.5 ml, Eporatio 4,000 UI/0.5 ml, and Eporatio 5,000 UI/0.5 ml: Each pre-filled syringe contains 0.5 ml of solution.
Packs of 6 pre-filled syringes; 6 pre-filled syringes with safety needles or 6 pre-filled syringes with safety devices.
Eporatio 10,000 UI/1 ml, Eporatio 20,000 UI/1 ml, and Eporatio 30,000 UI/1 ml: Each pre-filled syringe contains 1 ml of solution. Packs of 1, 4, and 6 pre-filled syringes; 1, 4, and 6 pre-filled syringes with safety needles or 1, 4, and 6 pre-filled syringes with safety devices.
Only some pack sizes may be marketed.
Marketing Authorization Holder
ratiopharm GmbH
Graf-Arco-Strasse 3
89079 Ulm
Germany
Manufacturer
Teva Biotech GmbH
Dornierstrasse 10
89079 Ulm
Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Teva Pharma Belgium N.V./S.A./AG Tel: +32 3 820 73 73 | Lithuania UAB "Sicor Biotech" Tel: +370 5 266 0203 |
Bulgaria Тева Фарма ЕООД Tel: +359 2 489 95 85 | Luxembourg ratiopharm GmbH, Germany Tel: +49 731 402 02 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 1 288 64 00 |
Denmark Teva Denmark A/S Tel: +45 44 98 55 11 | Malta Teva Pharmaceuticals Ireland, Ireland Tel: +353 51 321740 |
Germany ratiopharm GmbH Tel: +49 731 402 02 | Netherlands Teva Nederland B.V. Tel: +31 800 0228 400 |
Estonia UAB "Sicor Biotech" Estonian branch Tel: +372 661 0801 | Norway Teva Norway AS Tel: +47 66 77 55 90 |
Greece Teva Ελλάς Α.Ε. Tel: +30 210 72 79 099 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 007 |
Spain Teva Pharma, S.L.U. Tel: +34 91 387 32 80 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 22 345 93 00 |
France Teva Santé Tel: +33 1 55 91 78 00 | Portugal ratiopharm, Comércio e Indústria de Produtos Farmacêuticos, Lda Tel: +351 21 424 80 00 |
Croatia Pliva Hrvatska d.o.o. Tel: +385 1 37 20 000 | Romania Teva Pharmaceuticals S.R.L Tel: +40 21 230 65 24 |
Ireland Teva Pharmaceuticals Ireland Tel: +353 51 321740 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390 |
Iceland ratiopharm Oy, Finland Tel: +358 20 180 5900 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 2 57 26 79 11 |
Italy Teva Italia S.r.l. Tel: +39 02 89 17 98 1 | Finland ratiopharm Oy Tel: +358 20 180 5900 |
Cyprus Teva Ελλάς Α.Ε., Greece Tel: +30 210 72 79 099 | Sweden Teva Sweden AB Tel: +46 42 12 11 00 |
Latvia UAB "Sicor Biotech" Latvian branch Tel: +371 673 23 666 | United Kingdom Teva UK Limited Tel: +44 1977 628500 |
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
This section contains information on how to administer Eporatio injections under the skin. It is essential that you do not attempt to administer an injection without first receiving the necessary instructions from your doctor or nurse. If you are unsure about injecting yourself or have any doubts, consult your doctor or nurse.
How to Administer Eporatio
It should be injected into the tissue just under the skin. This is known as a subcutaneous injection.
Equipment Needed for Administration
To administer the injection under the skin, you will need:
What to Do Before Administering the Injection
2
3
How to Prepare for the Eporatio Injection
Before administering the Eporatio injection, do the following:
4
Where to Inject
The most suitable places for injection are:
If someone is helping you with the injection, you can also inject into the back and side of the arms (see the gray areas in image 6)
It is best to change the injection site every day to avoid the risk of pain in any of the areas.
5
6
How to Inject
7
8
Remember
If you have any problems, please ask for help or advice from your doctor or nurse.
How to Dispose of Used Syringes
This section contains information on how to administer Eporatio injections under the skin. It is essential that you do not attempt to administer an injection without first receiving the necessary instructions from your doctor or nurse. If you are unsure about injecting yourself or have any doubts, consult your doctor or nurse.
How to Administer Eporatio
It should be injected into the tissue just under the skin. This is known as a subcutaneous injection.
Equipment Needed for Administration
To administer the injection under the skin, you will need:
What to Do Before Administering the Injection
1
2
3
How to Prepare for the Eporatio Injection
Before administering the Eporatio injection, do the following:
4
5
Where to Inject
The most suitable places for injection are:
If someone is helping you with the injection, you can also inject into the back and side of the arms (see the gray areas in image 7)
It is best to change the injection site every day to avoid the risk of pain in any of the areas.
6
7
How to Inject
8
9
10
11
12
Remember
If you have any problems, please ask for help or advice from your doctor or nurse.
How to dispose of used syringes
The safety device prevents puncture injuries after use, so no special precautions are required for disposal. Dispose of syringes with safety devices according to the instructions of your doctor, pharmacist, or nurse.